The Effect of Methotrexate in Trophoblastic Diseases
Eleven patients with malignant trophoblastic neoplasia, six with choriocarcinoma and five with hydatidiform mole (three of them with invasive mole) were treated with methotrexate at a dose of 17.5–25 mg/daily for 2 to 5 days in repeat courses. One patient who was previously treated by hysterectomy for choriocarcinoma had no evidence of active growth at the onset of chemotherapy, but subsequently died. The remaining ten patients all had disseminated tumor and four of them exhibited signs of brain involvement. Eight patients responded by complete tumor regression and have remained free of disease on followup from 5 to 40 months. One patient died from disease and another from drug toxicity.